Why Look for Molecular Markers?

Depending on dose, firmonertinib shrank tumors in 43% to 68% of patients as a first treatment for EGFR PACC-mutant lung cancer in the phase 1b FURTHER trial.

U.S. counties where more residents had medical debt in collections had higher rates of late-stage lung, head and neck, colorectal and several other cancers, according to a study of 2,958 counties published in October 2026 in JAMA Network Open.

Libtayo survival data, a rare positive osteosarcoma trial and new ADCs for breast, lung and stomach cancers are among ESMO 2026 abstracts to watch.

Patients with a newly identified tumor state had shorter survival following chemotherapy and immunotherapy, potentially helping doctors identify those at greater risk of poor outcomes.

The FDA grants traditional approval to Keytruda and Keytruda Qlex for TMB-H solid tumors, updating the threshold to at least 13 mutations per megabase.

Martha Carlson reflects on her 11 years with metastatic breast cancer and explores how resilience, purpose and the stories we tell ourselves shape the cancer experience.

A study found that 1 in 9 older cancer survivors developed a second cancer, highlighting why routine screening remains important beyond five years.

After breast cancer at 30, Aisha shares her journey through motherhood, a double mastectomy, body image struggles and the challenges of survivorship.